UK markets closed

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.1899-0.1801 (-5.34%)
At close: 04:00PM EDT
3.2700 +0.08 (+2.51%)
After hours: 06:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3700
Open3.3100
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.1600 - 3.3100
52-week range1.7200 - 3.8400
Volume16,738
Avg. volume27,269
Market cap29.983M
Beta (5Y monthly)1.52
PE ratio (TTM)N/A
EPS (TTM)-5.6800
Earnings date21 Jun 2024 - 25 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.95
  • Insider Monkey

    12 Best Biotech Penny Stocks to Invest In

    In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]

  • GlobeNewswire

    Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

    Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission TimelinePoster Highlighting the STRIVE-ON Trial Presented at 2024 International Stroke Conference PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its n

  • GlobeNewswire

    Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

    Accepted for Presentation at the 2024 International Stroke ConferencePRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been a